New NCCN guidelines highlight personalized combo treatments and new options to help patients with advanced kidney cancer live ...
6d
NCCN 2026 Bladder Cancer Guidelines Adopt IBCG Risk Stratification Model for Intermediate-Risk NMIBC
The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best NASDAQ stocks under $30 to buy. On March 17, ImmunityBio announced that the National Comprehensive Cancer Network/NCCN updated its 2026 Clinical ...
ImmunityBio (IBRX) added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of ...
NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder ...
The MarketWatch News Department was not involved in the creation of this content.-- Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with pap ...
The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical ...
Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous squamous cell carcinoma (CSCC) ...
PLYMOUTH MEETING, PA [February 17, 2026] — The National Comprehensive Cancer Network ® (NCCN ®) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Pediatric Soft ...
PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results